- Endonovo
Therapeutics is developing a bioceutical device that provides an
alternative to the prescription pain pills blamed for hundreds of
thousands of deaths in recent years as part of a multinational opioid
crisis
- Endonovo’s
proprietary SofPulse® flagship device provides an electrical micro-current
to the afflicted part of the body, particularly post-surgery, to minimize
a patient’s need for pain relief medication
- A foot
and ankle specialist in Ohio recently used the device following her own
tendon surgery and provided a personal testimonial with a professional
perspective of the device’s effectiveness in minimizing her pain
- The
SofPulse® device is being evaluated professionally under a plan to be in
up to 600 U.S. hospitals by the end of next year
When a foot and ankle medical specialist underwent surgery
recently for her own tendon reconstruction need, she presented bioelectronic
device maker Endonovo
Therapeutics Inc. (OTCQB: ENDV) with a first-person professional
perspective of Endonovo’s non-opioid pain relief solution that showcases
Endonovo’s revolutionary potential for alleviating an international
drug-dependency crisis.
In a home-made video, Dr. Jane Graenber, DPM, of the Foot
and Ankle Wellness Center in Delaware, Ohio, attests that Endonovo’s SofPulse®
electroceutical device has helped her to remain generally pain-free a day after
the tendon surgery, such that she says she has only used three doses of Tylenol
for relief (no prescription pain pills) during the interim since her
procedure (http://ibn.fm/H2n5X).
“This device is putting out a micro-current to my surgical
area every two hours… And it’s taken care of the pain, and I’m sitting here very
comfortably,” Graenber states in the video. “At our practice we may be starting
to include this post-operatively as an option to reduce pain. This was a pretty
big surgery and I’m really very comfortable. So I’m giving credit to a good
surgeon but also a new device that may revolutionize pain (treatment) after
surgery.”
Endonovo announced its initial strategy to begin a national
rollout of the SofPulse® on June 13 with plans to be in the evaluation stage at
600 U.S. hospitals through the end of next year (http://ibn.fm/P0w4a). Graenber
identifies the video’s date as August 3, countering a time stamp at the bottom
of the video that says it was recorded in January 2015.
The proliferation of opioids for pain relief following
medical procedures during the past two decades has generated worldwide concerns
about the prescription pills’ apparent role in creating patients’ ensuing drug
addictions – addictions that have been cited in the deaths of hundreds of thousands
of people. The Centers for Disease Control and Prevention states that as of
2017, its statistics showed an average of 130 Americans were dying every day
from an opioid overdose (http://ibn.fm/4e49T).
The concerns about opioid abuse have sparked a
multi-national sea change in attitudes regarding marijuana use as a medical
therapy, although the cannabis plant’s products remain controversial with many
governmental regulators. Endonovo’s SofPulse® provides a non-drug alternative
to treating pain relief, entirely bypassing concerns about potential substance
abuse and harmful side effects.
Furthermore, a recent scientific study of patient outcomes
is countering the popularly held idea that marijuana reform is reducing the
number of opioid-related deaths. The study published in the Proceedings of the
National Academy of Sciences of the United States of America (PNAS) in June
found that states where cannabis legislation has eased access to medical
marijuana as an alternative to opioids have actually seen an increase in
opioid-related deaths in recent years, rather than a decrease (http://ibn.fm/0BsyR).
“Cannabinoids have demonstrated therapeutic benefits, but
reducing population-level opioid overdose mortality does not appear to be among
them,” the study states.
Endonovo’s therapy platform has received clearance for the
palliative treatment of post-operative pain and swelling from the U.S. Federal
Drug Administration, insurance coverage for chronic wound treatment from the
national Centers for Medicare and Medicaid Services, and a CE-mark
certification that denotes conformity with European Economic Area health and
environmental standards related to wound, pain and edema treatment.
For more information, visit the company’s website at www.Endonovo.com
NOTE TO INVESTORS: The latest news and updates
relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment